Clinical trials: Pulmonary Aspergillosis
Allergic Bronchopulmonary Aspergilloses
A Study Evaluating Vitamin D in Allergic Bronchopulmonary Aspergillosis Complicating Asthma
Allergic bronchopulmonary aspergillosis (ABPA) is a immunological pulmonary disorder caused by hypersensitive reaction to spores of Aspergillus fumigatus.
- Trial name
- NCT03133299
- Testing
- Glucocorticoids, Vitamin D
- Where
- India
- Volunteers
- 30 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Survival After IPA, Risk Factors for IPA
Diagnosis of Invasive Pulmonary Aspergillosis (IPA) in Critically Ill Patients
Invasive pulmonary aspergillosis (IPA) is difficult to diagnose and remains a cause of high morbidity and mortality in critically ill patients in the ICU.
- Trial name
- DipA (NCT01866020)
- Where
- Germany
- Volunteers
- 85 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Chronic Pulmonary Aspergillosis
Impact of Chronic Pulmonary Aspergillosis (CPA) on Health Status and Well-being
To develop and validate a novel disease-specific questionnaire for measuring HRQoL in patients with Chronic Pulmonary Aspergillosis (CPA-HAQ) for use in clinical research, including clinical trials.
- Trial name
- CAPSULE (NCT06885905)
- Where
- 3 sites in United Kingdom
- Volunteers
- 100 people
- Sponsor
- Imperial College London
Influenza With Pneumonia, Invasive Pulmonary Aspergillosis
Influenza Associated Aspergillosis In-depth Investigation
This trial is aimed to study the immunological and pathological characteristics of influenza versus non-influenza severe community-acquired pneumonia patients in ICU.
- Trial name
- PIAS (NCT03748069)
- Where
- Belgium
- Volunteers
- 45 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Candidemia, Aspergillosis Invasive
Performance Evaluation of the Fujifilm Wako Beta-D-glucan Technique in the Diagnosis of Major Invasive Fungal Infections (IFI)
Invasive fungal infections (IFI) are a major concern for immunocompromised or vulnerable patients. Associated mortality is significant and depends on the timeliness of diagnostic and therapeutic management.
- Conditions
- Candidemia, Aspergillosis Invasive, Pneumocystosis; Pneumonia (Etiology), IFI
- Trial name
- NCT07272915
- Testing
- Beta-1,3/1,6-D-Glucan
- Where
- France
- Volunteers
- 280 people
- Sponsor
- Central Hospital, Nancy, France
Severe COVID-19
COVID-19 and VA-LRTI: Second Versus First Wave of the Pandemic
Multicenter observational retrospective cohort study aiming at comparing the incidence of ventilator-associated lower respiratory tract infections between COVID-19 patients from the first and the second wave of the pandemic.
- Trial name
- CoVAPid2 (NCT05256511)
- Where
- France
- Sponsor
- University Hospital, Lille
Allergic Bronchopulmonary Aspergillosis
Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)
The primary objective of the study is to evaluate the efficacy of dupilumab on lung function in participants with Allergic Bronchopulmonary Aspergillosis (ABPA).
- Trial name
- NCT04442269
- Testing
- dupilumab
- Where
- 50 sites in United States, Bulgaria and 8 more
- Volunteers
- 62 people
- Sponsor
- Regeneron Pharmaceuticals
Chronic Pulmonary Aspergillosis
Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA)
This study evaluates and aims to optimize inhalation treatment with nebulized liposomal amphotericin B in patients with chronic pulmonary aspergillosis.
- Trial name
- NIMBUS (NCT07530263)
- Testing
- 12 mg of nebulised 99mTc-liposomal amphotericin B, 24 mg of nebulised 99mTc-liposomal amphotericin B, SPECT/CT scan
- Where
- Netherlands
- Volunteers
- 18 people
- Sponsor
- Radboud University Medical Center
Cystic Fibrosis
Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients
This study is designed to assess the safety, tolerability, pharmacokinetics and preliminary pharmacodynamics (proof of concept) of QBW251 in healthy subjects and cystic fibrosis patients following single and multiple doses.
- Trial name
- NCT02190604
- Testing
- QBW251
- Where
- 23 sites in United States, Belgium and 5 more
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Diphtheria, Acellular Pertussis
Impact of Boostrix™ Maternal Vaccination on Morbidity and Mortality of Pertussis Disease in Infants ≤6 Weeks of Age, in Bogota, Colombia.
This study is being conducted to assess impact of maternal immunisation against pertussis in infants ≤12 months of age before and after introduction of pertussis maternal immunisation in Bogota, Colombia from January…
- Conditions
- Diphtheria, Acellular Pertussis, Tetanus, Aspergillosis, Allergic Bronchopulmonary
- Trial name
- NCT02569879
- Testing
- Pertussis maternal immunization
- Where
- Colombia
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Chronic Pulmonary Aspergillosis
Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment Options
The goal of this clinical trial is to to evaluate the drug rezafungin in the treatment of Chronic Pulmonary Aspergillosis (CPA) in male and female patients aged 18 years and over with limited treatment options.
- Trial name
- NCT06794554
- Testing
- Rezafungin Acetate
- Where
- 37 sites in Austria, Belgium and 8 more
- Volunteers
- 60 people
- Sponsor
- Mundipharma Research Limited
Asthma
Pharmacokinetic Profile of Voriconazole Inhalation Powder in Adult Subjects With Asthma
This is a Phase 1b, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability, and pharmacokinetic profiles of voriconazole inhalation powder in adult subjects with well-controlled asthma.
- Trial name
- NCT04576325
- Testing
- Voriconazole Inhalation Powder
- Where
- Australia
- Volunteers
- 17 people
- Sponsor
- TFF Pharmaceuticals, Inc.
Aspergillosis, Lung Transplant Infection
The Effect of Early Treatment of PC945 on Aspergillus Fumigatus Lung Infection in Lung Transplant Patients.
This study tests the effects of pre-emptive treatment with an experimental drug PC945 in lung transplant recipients whose lungs are infected by the fungus Aspergillus fumigatus.
- Trial name
- NCT03905447
- Testing
- PC945, Standard of Care
- Where
- 3 sites in United Kingdom
- Volunteers
- 2 people
- Sponsor
- Pulmocide Ltd
Cystic Fibrosis, Allergic Bronchopulmonary Aspergillosis
Mechanisms of Immune Tolerance and Inflammation in Patients With Cystic Fibrosis With ABPA
The goal of this study is to identify the immunological factors that influence a patient's response to the presence of the fungus Aspergillus fumigatus (A. fumigatus) in the lungs.
- Trial name
- ABPA (NCT00585364)
- Where
- United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Infection, Pulmonary Complications
Comparison of Voriconazole and Amphotericin B in Treating Patients With Aspergillosis
RATIONALE: Antifungal therapy with voriconazole or amphotericin B may be an effective treatment for aspergillosis. It is not yet known whether voriconazole is more effective than amphotericin B in treating patients with…
- Trial name
- NCT00003031
- Testing
- amphotericin B deoxycholate, voriconazole
- Where
- 74 sites in United States, Australia and 13 more
- Volunteers
- 212 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Anaemia, Aspergillosis, Allergic Bronchopulmonary
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)
The purpose of this multi-center event-driven study in participants with anemia associated with chronic kidney disease (CKD) to evaluate the safety and efficacy of daprodustat.
- Trial name
- NCT02879305
- Testing
- Daprodustat, rhEPO, Iron therapy
- Where
- 462 sites in United States, Argentina and 33 more
- Volunteers
- 2,964 people
- Sponsor
- GlaxoSmithKline
Aspergillosis
Voriconazole For Chronic Bronchopulmonary Aspergillosis
To evaluate the efficacy of voriconazole (VFend(R)) as first line treatment for proven chronic bronchopulmonary aspergillosis, in minimally immunocompromised or non-immunocompromised patients after 6 months of treatment i.e.
- Trial name
- NCT00159822
- Testing
- Voriconazole
- Where
- 18 sites in France
- Volunteers
- 48 people
- Sponsor
- Pfizer
Immunocompromised Host, Invasive Pulmonary Fungal Infection
Early Molecular Detection for the Improved Diagnosis of Invasive Pulmonary Aspergillosis and Invasive Pulmonary Zygomycosis
Background: Fungal infections of the lung (pneumonia) can be caused by molds, such as Aspergillus and Zygomycetes, but these causes are often difficult for a doctor to diagnose.
- Conditions
- Immunocompromised Host, Invasive Pulmonary Fungal Infection, Invasive Pulmonary Aspergillosis, Invasive Pulmonary Zygomycosis
- Trial name
- NCT00923832
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Allergic Bronchopulmonary Aspergillosis (ABPA)
Pathogenesis and Inflammatory Phenotype of Allergic Bronchopulmonary Aspergillosis
This study aims to reveal the immune and inflammatory regulatory molecular mechanisms related to the progression of allergic bronchopulmonary aspergillosis (ABPA), and to build a precision typing based on inflammation and…
- Trial name
- NCT07040332
- Where
- China
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Qianfoshan Hospital
Aspergillosis, Invasive Pulmonary
PCR Based Detection of Azole Resistance in A. Fumigatus to Improve Patient Outcome.
A standard treatment protocol for invasive aspergillosis (IA) will be implemented in several academic hematology centers in the Netherlands in which a diagnostic test demonstrating azole resistance by multiplex real-time…
- Trial name
- AzorMan (NCT03121235)
- Testing
- PCR based detection of azole resistance in A. fumigatus
- Where
- 8 sites in Netherlands
- Volunteers
- 320 people
- Sponsor
- Erasmus Medical Center